^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | KT-413 (IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
013 | KT-413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE-AGENT AND COMBINATION REGRESSIONS IN MYD88MT LYMPHOMA MODELS
Published date:
06/09/2021
Excerpt:
In MYD88MT DLBCL xenograft models, a single IV dose of KT-413 showed significant and sustained degradation of both IRAK4 and the IMiD substratesl…KT-413 was well tolerated and showed potent antitumor activity in multiple models of MYD88MT DLBCL…
